Yukiya Narita
0000-0002-8018-0077
Publication & Citation Trends
Publications
0 total
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.
Cited by 0
Semantic Scholar
Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study
Cited by 0
Semantic Scholar
Regorafenib in refractory gastric cancer: modest median, meaningful milestone
Cited by 0
Semantic Scholar
ANGPTL3 in the peripheral circulation is associated with resistance to anti-PD1 therapy in advanced gastric cancer.
Cited by 0
Semantic Scholar
Effect of peripheral ANGPTL3 on the efficacy of anti-PD1 therapy for advanced gastric cancer.
Cited by 0
Semantic Scholar
Randomized phase II trial evaluating the efficacy of zolbetuximab in the second-line for claudin18.2 positive advanced gastric/EGJ cancer patients previously treated with zolbetuximab and platinum-based chemotherapy (ZELDA trial).
Cited by 0
Semantic Scholar
Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative
Cited by 6
Semantic Scholar
IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer
Cited by 1
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(117)
Colorectal Cancer Treatments and Studies
(68)
Cancer Immunotherapy and Biomarkers
(36)
Gastrointestinal Tumor Research and Treatment
(29)
Cancer Treatment and Pharmacology
(25)
Affiliations
The University of Texas MD Anderson Cancer Center
Orlando Health
Jilin University
Washington University in St. Louis
Osaka City University